Engineered immune cells take on childhood cancers in first human test
NCT ID NCT03618381
First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells carrying a protein called EGFR. The study will enroll 44 participants to evaluate safety, find the best dose, and see if the cells can shrink tumors. Some participants will receive cells that also target a second protein (CD19) to help the immune cells work longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EGFR806 CAR T cells (genetically modified immune cells)
What this could lead to
If successful, this could point toward a new treatment option for children and young adults with hard-to-treat solid tumors that have come back or not responded to standard therapy.
What could go wrong
This is an early Phase 1 trial with only 44 participants, so it is primarily testing safety and dosing. The treatment may not shrink tumors, and there are risks of serious side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.